Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Nov;32(11):2047-9.
doi: 10.2337/dc09-0846. Epub 2009 Aug 12.

Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Bruce Bode, Roy W Beck, Dongyuan Xing, Lisa Gilliam, Irl Hirsch, Craig Kollman, Lori Laffel, Katrina J Ruedy, William V Tamborlane, Stuart Weinzimer, Howard Wolpert
Collaborators
Randomized Controlled Trial

Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group et al. Diabetes Care. 2009 Nov.

Abstract

Objective: To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively treated adults with type 1 diabetes.

Research design and methods: We studied 83 of 86 individuals >or=25 years of age with type 1 diabetes who used CGM as part of a 6-month randomized clinical trial in a subsequent 6-month extension study. RESULTS After 12 months, median CGM use was 6.8 days per week. Mean change in A1C level from baseline to 12 months was -0.4 +/- 0.6% (P < 0.001) in subjects with baseline A1C >or=7.0%. A1C remained stable at 6.4% in those with baseline A1C <7.0%. The incidence rate of severe hypoglycemia was 21.8 and 7.1 events per 100 person-years in the first and last 6 months, respectively. Time per day with glucose levels in the range of 71-180 mg/dl increased significantly (P = 0.02) from baseline to 12 months.

Conclusions: In intensively treated adults with type 1 diabetes, CGM use and benefit can be sustained for 12 months.

Trial registration: ClinicalTrials.gov NCT00406133.

PubMed Disclaimer

References

    1. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008359:1464–1476 - PubMed
    1. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378–1383 - PMC - PubMed
    1. JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther 2008;10:310–321 - PubMed
    1. Gibb I, Parnham A, Fonfrède M, Lecock F: Multicenter evaluation of Tosoh glycohemoglobin analyzer. Clin Chem 1999;45:1833–1841 - PubMed
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - PubMed

Publication types

Associated data